DeepMed Research

Tianjin Medical University Cancer Institute & Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Phase 2

Recruiting

Conditions: Resectable Biliary Tract Cancer

Interventions: Drug: Cisplatin
Drug: Gemcitabine
Drug: Nab-paclitaxel
Drug: Durvalumab

First Posted Date: 2022-12-07

Last Posted Date: 2022-12-07

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 40

Registration Number: NCT05640791

Locations: 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China

Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Esophagus Cancer

Interventions: Drug: Camrelizumab
Drug: Paclitaxel
Drug: Cisplatin

First Posted Date: 2022-12-05

Last Posted Date: 2022-12-05

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 23

Registration Number: NCT05637268

Locations: 🇨🇳
Affiliated Cancer Hospital of Tianjin Medical University, Tianjin, Tianjin, China

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

Phase 2

Recruiting

Conditions: Neuroendocrine Tumor Grade 3
Neuroendocrine Carcinoma
Pancreatic Carcinoma

Interventions: Drug: Surufatinib
Drug: Sintilimab

First Posted Date: 2022-11-25

Last Posted Date: 2022-11-25

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 60

Registration Number: NCT05627427

Locations: 🇨🇳
Rui Liu, Tianjin, Tianjin, China

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Drug: Disitamab Vedotin
Drug: Sintilimab
Drug: S-1
Procedure: Intraperitoneal chemotherapy with paclitaxel

First Posted Date: 2022-11-25

Last Posted Date: 2022-11-25

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT05627414

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

Not Applicable

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: HAIC
Drug: Sintilimab
Drug: Lenvatinib

First Posted Date: 2022-11-18

Last Posted Date: 2022-11-18

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 60

Registration Number: NCT05621499

Locations: 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.

Phase 2

Recruiting

Conditions: Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Interventions: Drug: tislelizumab+GEMOX
Drug: tislelizumab+lenvatinib+GMOX

First Posted Date: 2022-11-17

Last Posted Date: 2022-11-17

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 60

Registration Number: NCT05620498

Locations: 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Sintilimab
Drug: Bevacizumab
Combination Product: Liver Protective Support Therapy

First Posted Date: 2022-11-15

Last Posted Date: 2023-03-21

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT05616390

Locations: 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer

Phase 2

Recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: Tislelizumab
Radiation: Pulse radiation

First Posted Date: 2022-10-27

Last Posted Date: 2022-10-27

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 20

Registration Number: NCT05595590

Locations: 🇨🇳
Sichuan Cancer Hosiptal, Chengdu, Sichuan, China
🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Early Detection of Pancreatic Cancer

Recruiting

Conditions: Pancreatic Cancer

Interventions: Other: No intervention

First Posted Date: 2022-10-27

Last Posted Date: 2022-10-27

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 496

Registration Number: NCT05596435

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma

Phase 2

Not yet recruiting

Conditions: Objective Response Rate (ORR)

Interventions: Drug: Envafolimab, Lenvatinib Combined With TACE

First Posted Date: 2022-10-17

Last Posted Date: 2022-10-17

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT05582109

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy